Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Overview

This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

Full Title of Study: “A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2016

Detailed Description

PRIMARY OBJECTIVES: I. To determine whether the addition of plerixafor improves the proportion of patients with lymphoma who collect >= 8 x 10^6 cluster of differentiation (CD)34+ cells/kg within two days by 25% compared to the historical estimate of 42% with etoposide and G-CSF (filgrastim). II. To determine whether patients achieving collection of >= 8 x 10^6 CD34+ cells/kg have a 15% one year survival advantage relative to the historical estimate of 68% among patients mobilizing >= 2 but < 8 x 10^6 CD34+ cells/kg with etoposide and G-CSF. SECONDARY OBJECTIVES: I. To demonstrate that patients receiving >= 8 x 10^6 CD34+ cells/kg have more rapid neutrophil and platelet recovery and earlier hospital discharge than those receiving < 8 x 10^6 CD 34+ cells/kg. II. To compare overall survival and progression-free survival between patients receiving >= 8 x 10^6 CD34+ cells/kg and those receiving < 8 x 10^6 CD34+ cells/kg. III. To compare number of days of apheresis required to achieve goal, transfusion requirements, hospitalization costs, need for remobilization between groups. IV. To evaluate whether peripheral CD34+ cell count correlates with graft content of CD34+ cells. OUTLINE: Patients receive etoposide intravenously (IV) over 4 hours on day 0, filgrastim subcutaneously (SC) once daily (QD) beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. After completion of study treatment, patients are followed up at 28 days and then for at least 1 year.

Interventions

  • Drug: plerixafor
    • Given SC
  • Biological: filgrastim
    • Given SC
  • Drug: etoposide
    • Given IV
  • Procedure: leukapheresis
    • Undergo apheresis

Arms, Groups and Cohorts

  • Experimental: Treatment (stem cell supermobilization)
    • Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.

Clinical Trial Outcome Measures

Primary Measures

  • Collection Using Plerixafor, Etoposide, and Filgrastim
    • Time Frame: Within 2 days of apheresis
    • Number of participants able to collect equal to or more than 8 x 10^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10^6 CD34+ cells/kg are defined as normal mobilizers.
  • Progression-free Survival
    • Time Frame: Up to 1 year post-transplant
    • The number of participants of patients who receive greater than or equal to 8 x 10^6 CD34+ cells/kg following collection with plerixafor, etoposide, and filgrastim and that have progression-free survival at one year
  • Overall Survival
    • Time Frame: Up to 1 year post-transplant
    • Number of participants who receive greater than or equal to 8 x 10^6 CD34+ cells/kg by 15% following collection with plerixafor, etoposide, and filgrastimstill alive at 1 yr post transplant

Secondary Measures

  • Neutrophil Recovery in Super Mobilizers and Normal Mobilizers
    • Time Frame: Up to 28 days post treatment
    • Neutrophil recovery in participants receiving greater than or equal to 8 and less than 8 x 10^6 CD34+ cells/kg entered as the mean cell count of super mobilizers and normal mobilizers.
  • Platelet Recovery in Super Mobilizers and Normal Mobilizers
    • Time Frame: Up to 28 days post treatment
    • Platelet recovery in participants receiving greater than or equal to 8 and less than 8 x 10^6 CD34+ cells/kg.
  • Length of Hospital Stay in Super Mobilizers and Normal Mobilizers
    • Time Frame: Up to 28 days post treatment
    • Length of hospital stay in participants receiving greater than or equal to 8 and less than 8 x 10^6 CD34+ cells/kg.
  • Progression-free Survival in Supermobilizers and Normal Mobilizers
    • Time Frame: Up to 1 year post-transplant
    • Percentage of participants who were alive and free of progression 1 year after transplant (PFS)
  • Overall Survival in Supermobilizers and Normal Mobilizers
    • Time Frame: Up to 1 year post-transplant
    • Percentage of participants who were alive 1 year after transplant (OS)
  • Number of Days of Apheresis Required
    • Time Frame: Up to 28 days post treatment
    • Number of days of apheresis required to achieve goal in supermobilizers and normal mobilizers
  • Number of Transfusion Requirements
    • Time Frame: Up to 28 days post treatment
    • Number of transfusions (number of packed red blood cells and platelet transfusions required from day 0 to +28 post-transplant) in supermobilizers and normal mobilizers
  • Need for Remobilization
    • Time Frame: Up to 28 days post treatment
    • Number of participants that needed remobilization in supermobilizers and normal mobilizers. Remobilization can be described as follows: The first step for patients undergoing autologous hematopoietic cell transplantation is to mobilize hematopoietic progenitor/stem cells from the bone marrow using G-CSF, plerixafor and/or chemotherapy. This is followed by collection of the cells by apheresis. If sufficient number of progenitor/stem cells cannot be mobilized and then collected by apheresis to proceed with transplantation, it is considered as “mobilization failure”. For these patients, mobilization of their hematopoietic progenitor/stem cells is attempted a second time (“remobilization”). The need to do a second ‘mobilization’ attempt is not ideal.
  • Correlation of Peripheral CD34+ Cell Count With Graft Content of CD34+ Cells
    • Time Frame: Up to 28 days post treatment
    • Correlation of peripheral CD34+ cell count with graft content of CD34+ cells assessed using Spearman correlation.

Participating in This Clinical Trial

Inclusion Criteria

  • Have biopsy-confirmed non-Hodgkin lymphoma, of any type – Must be eligible for autologous transplantation according to institutional guidelines – Eastern Cooperative Oncology Group performance status of 0 or 1 – Karnofsky performance status of 70 to 100 – Negative for human immunodeficiency virus (HIV) – prior to the start of mobilization, subjects must have: – Absolute neutrophil count of >= 1.2 x 10^9/L – Platelet count of >= 100 x 10^9/L – Creatinine clearance >= 30 mL/minute – All patients must be able to comprehend and sign informed consent – If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy Exclusion Criteria:

  • Have had previous transplants and/or prior mobilization attempts – Have evidence of progressive non-Hodgkin lymphoma – Have evidence of bone marrow involvement of lymphoma at time of transplant staging – Had evidence of active central nervous system (CNS) involvement – Have had previous radiation of the pelvic area – Have had prior radioimmunotherapy – Have received experimental therapy within 2 weeks of enrollment – Be currently enrolled in another investigational protocol – Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 78 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Case Comprehensive Cancer Center
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Navneet Majhail, MD, Principal Investigator, Case Comprehensive Cancer Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.